TamirBio initial clinical target is the treatment of genital warts caused by HPV. Worldwide, there are 14 million new and recurrent genital wart infections caused by HPV (the most common sexually transmitted disease). Today’s therapeutic options all have shortcomings including high rates of recurrence, the need for continued application, or invasiveness. TamirBio asserts that clinicians and patients will adopt a topically applied option that demands only 1-2 applications with a high safety profile.
TamirBio estimates the total HPV market opportunity at $1.4B.
4th largest threat
The U.S. Center for Disease Control and Prevention (CDC) has named HPV the 4th largest health threat the U.S. will face in 2014
While several types of HPV have been linked with cervical cancer, HPV types 16 and 18 are thought to account for roughly 70% of all cervical cancer cases
Persistent HPV infection in the anal region is thought to be responsible for up to 80% of anal cancers.
According to the CDC, the number of people who contract genital warts in the US every year.
TamirBio is currently enrolling a phase I OUS study of topical ranpiranse for anogential warts. Results are expected in Q1 2015.
Beyond HPV, TamirBio has documented considerable anti-viral activity for the following licensing opportunities:
TamirBio ranpirnase is actively being considered as a standalone or adjuvant therapy in an effort to battle the recent worldwide EBV outbreaks.
Reported to be between 500,000 and 1 million deaths/year from influenza.
Middle East Respiratory Syndrome (MERS-CoV)
Expanding disease outbreak, with a total of just under 1,000 cases confirmed by World Health Organization.
Hepatitis C Virus (HCV)
Cost-effective treatment of HCV remains a worldwide challenge, despite the recent approval of new, efficacious HCV therapies.
CMV disease is a common condition post-renal transplant, despite prophylaxis.
The CDC reported the highest number of RSV in the United States in the past 15 years due to an increasing number of individuals not vaccinated.
55,000 deaths/year confirmed by World Health Organization.
Human Immunodeficiency Virus (HIV)
Laboratory evaluation has demonstrated that ranpirnase is effective in inhibiting infection of epithelial cells by Human Immunodeficiency Virus (HIV). This approach will serve important in using topical ranpirnase to prevent the spread of HIV.